Tesamorelin

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that has been the subject of extensive research in the field of endocrinology and metabolism. This peptide's primary mechanism of action involves binding to and activating the growth hormone-releasing hormone receptor (GHRHR) in the anterior pituitary gland. This activation stimulates the synthesis and pulsatile release of endogenous growth hormone (GH), which in turn promotes the production of insulin-like growth factor-1 (IGF-1) in the liver and other tissues.

• Visceral Adipose Tissue (VAT) Reduction: Clinical studies have shown that tesamorelin can significantly reduce VAT in study subjects with HIV-associated lipodystrophy and in obese study subjects without HIV. This reduction in VAT has been associated with improvements in metabolic health markers.

• Insulin Sensitivity: Investigations have indicated that tesamorelin treatment may improve insulin sensitivity in certain populations, including study subjects with HIV-associated lipodystrophy and obese study subjects without HIV.

• Cognitive Function: Some studies have explored tesamorelin's potential effects on cognitive function in older adults with mild cognitive impairment (MCI). Preliminary findings suggest possible improvements in executive function, attention, and memory.

• Muscle Mass and Strength: Research has indicated that tesamorelin may increase muscle mass and strength in older adults and study subjects with HIV-associated lipodystrophy.

• Bone Health: Studies have observed increases in bone mineral density (BMD) in study subjects with HIV-associated lipodystrophy following tesamorelin treatment.

Handle as a laboratory research chemical of unknown hazard. Use gloves and eye protection, avoid inhalation of the lyophilized powder, and follow standard laboratory handling procedures.

Reconstitute and store according to the product label. Lyophilized material should be kept cool, dry and protected from light; reconstituted material should be held at 2-8°C and protected from light.

The safety profile of Tesamorelin has not been established. This compound is supplied for laboratory research use only and is not approved for human or veterinary use.

Tesamorelin is a potent growth hormone-releasing hormone (GHRH) analog that has been extensively researched for its potential to improve metabolic health, reduce visceral adipose tissue (VAT), and enhance cognitive function in various populations. By stimulating the production and release of endogenous growth hormone (GH) from the anterior pituitary gland, tesamorelin promotes the production of insulin-like growth factor-1 (IGF-1), leading to numerous metabolic and cognitive benefits. Studies have demonstrated that tesamorelin significantly reduces VAT, improves insulin sensitivity, enhances cognitive function, increases muscle mass and strength, and promotes bone health in study subjects with HIV-associated lipodystrophy, obesity, and age-related cognitive decline. As a research peptide, tesamorelin holds promise for further investigating the complex interplay between growth hormone, metabolism, and cognitive function, potentially leading to the development of novel research approaches for various metabolic and cognitive disorders.